http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201492271-A1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-52 |
filingDate | 2013-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2015-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EA-201492271-A1 |
titleOfInvention | CHROMAN CONNECTIONS |
abstract | The invention relates to a compound that is useful as an active ingredient in a pharmaceutical composition, in particular a pharmaceutical composition for the prevention or treatment of conditions associated with and / or mediated by β-secretase activity, hydrolysis of the β-secretase cleavage site of the amyloid precursor protein and / or protein accumulation β-amyloid, including pharmaceutical compositions for prophylaxis or treatment, including without limitation glaucoma, MCI (mild cognitive impairment) or Alzheimer's disease, mainly Alzheimer's disease. |
priorityDate | 2012-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.